Industry News
Excerpt from the Press Release: A 58-year-old Montrealer is the first patient in Quebec to receive a transplant of lab-grown cells to help treat his Type 1 diabetes — a milestone in an international clinical trial underway at the McGill University Health Centre (MUHC). Bruno Houde, who was diagnosed with the disease at age seven,…
Read More
Data continue to demonstrate favorable safety and efficacy profile, including earlier and deeper responses in cohort 3 compared to cohorts 1-2 Data to be presented in an oral session and poster at the Society for Investigative Dermatology 2025 Annual Meeting Company to discuss data today on its first quarter 2025 business update conference call and…
Read More
Multicenter study sponsored by SELNET to evaluate cirtuvivint as a second-line monotherapy in selected sarcoma subtypes Excerpt from the Press Release: SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) — Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering advancements in small molecule inhibition of CDC-like kinases (CLK) and Dual-specificity tyrosine phosphorylation-regulated (DYRK) kinases, today announced…
Read More
TrialStat will be showcasing our cutting-edge EDC Platform with integrated Medical Imaging Workflow Platform at the COG DMV meeting in Bethesda, Maryland on May 13th – 14th. This conference provides an exceptional opportunity for in-depth discussions on how our platform is advancing clinical research and streamlining clinical trial execution for Sponsors and CROs. Meet with…
Read More
Groundbreaking device sets new standard in the management of patients with an elevated risk of sudden cardiac arrest Excerpt from the Press Release: SAN FRANCISCO–(BUSINESS WIRE)–In a significant leap forward in the care of patients with cardiac disease, Element Science is proud to announce that its innovative Jewel® Patch Wearable Cardioverter Defibrillator (Patch-WCD) has received…
Read More
Excerpt from the Press Release: PHILADELPHIA and VANCOUVER, British Columbia, April 24, 2025 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, confirms the sustained complete resolution of the lung metastasis, first reported in February 2025, two months…
Read More
Excerpt from the Press Release: PHILADELPHIA and VANCOUVER, British Columbia, April 10, 2025 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, and its majority owned subsidiary, BriaPro Therapeutics Corp. (“BriaPro”), are pleased to announce that BriaPro is developing novel,…
Read More
Excerpt from the Press Release: PALO ALTO, Calif., April 16, 2025 (GLOBE NEWSWIRE) — Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, following the formation of its proposed joint venture with IPMC Company,…
Read More
TrialStat will be showcasing our cutting-edge EDC Platform with integrated Medical Imaging Platform at the COG New England Meeting in Burlington, Massachusetts on April 28th – 30th. This conference provides an exceptional opportunity for in-depth discussions on how our platform is advancing clinical research and streamlining clinical trial execution for Sponsors and CROs. Meet with…
Read More
Collaboration partner, Gilead Sciences, to begin Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) study in healthy volunteers in Q2 2025 GS-6791/NX-0479 has potential clinical applications across multiple blockbuster markets in inflammation, in both rheumatology and dermatology, including rheumatoid arthritis and atopic dermatitis Nurix to receive a $5 million milestone payment from…
Read More